Vonafexor accepted as the generic name for EYP001 by the WHO

We are pleased to announce that the World Health Organization (WHO) has accepted the international non-proprietary name (INN, or generic name) vonafexor for our FXR agonist lead candidate previously referred to as EYP001. Read next in 'Latest news' Enrollment completed for our Phase 2 clinical trial in Alport syndrome The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH

The release as fetched from its publisher. enyopharma.com ↗